Hi tada.

Thanks for the perspective but I'm not sure I fully understand what you are saying. So here are my thoughts;

1. from what you say I feel apabetalone doesn't have a chance unless it finds a partner that does not already have a drug treating any one of these indications
2. RVX requires excellent talent on the business side (which is it's biggest weakness) to even have a chance of getting to market
3. as I understand it Eversana is dormant at this time because RVX can't pay them. Therefore they do not have a business development function at this stage.

I've never seen any evidence of competence in the RVX management team.

And yet we have Eastern, NGN, Hepa, etc still being shareholders (essentially because they have no reasonable exit options).

I'm rambling here, but a final thought is that I am surprised at how weak Hepalink is as a partner. They did nothing on Covid in spite of huge problems in  China, they didn't keep BoM moving and they are not providing funds to get the next stage happening.

Unless apabetalone gets an extremely successful trial and an NDA there really seems to be no hope. And this will take years and big $$$$ to achieve. Seems hopeless and impossible with this management team.

I remain long for reasons stated many times before.

GLTA 

Toinv